Cargando…

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination and poor prognosis. We evaluated the novel CXCR4 probe [(68)Ga]Pentixafor for in vivo mapping of CXCR4 expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Philipp-Abbrederis, Kathrin, Herrmann, Ken, Knop, Stefan, Schottelius, Margret, Eiber, Matthias, Lückerath, Katharina, Pietschmann, Elke, Habringer, Stefan, Gerngroß, Carlos, Franke, Katharina, Rudelius, Martina, Schirbel, Andreas, Lapa, Constantin, Schwamborn, Kristina, Steidle, Sabine, Hartmann, Elena, Rosenwald, Andreas, Kropf, Saskia, Beer, Ambros J, Peschel, Christian, Einsele, Hermann, Buck, Andreas K, Schwaiger, Markus, Götze, Katharina, Wester, Hans-Jürgen, Keller, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403048/
https://www.ncbi.nlm.nih.gov/pubmed/25736399
http://dx.doi.org/10.15252/emmm.201404698
Descripción
Sumario:CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination and poor prognosis. We evaluated the novel CXCR4 probe [(68)Ga]Pentixafor for in vivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [(68)Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [(68)Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [(18)F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34(+) flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [(68)Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases.